LOS ANGELES, March 05, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network owned and operated outpatient imaging centers, today announced that Gregory Sorensen, M.D., Chief Science Officer of RadNet and President of DeepHealth (RadNet’s Artificial Intelligence Division) and Sham Sokka, Chief Operating & Technology Officer of RadNet’s Digital Health, will be presenting at the Cowen & Company Healthcare Conference on Wednesday, March 6, 2024 at 2:10 p.m. Eastern Time.
There will be simultaneous and archived webcasts available here and www.radnet.com under the “About RadNet” menu section and “News and Press Releases” sub-menu of the website.
Details for RadNet’s Presentation: | |
Date: Time: URL: | Wednesday, March 6, 2024 2:10 p.m. Eastern Time /webcast/cowen154/register.aspx?conf=cowen154&page=rdnt&url=https://wsw.com/webcast/cowen154/rdnt/2031632 |
About RadNet, Inc.
RadNet, Inc., is the leading national provider of freestanding, fixed-site diagnostic imaging services and related information technology solutions (including artificial intelligence) in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 366 owned and/or operated outpatient imaging centers. RadNet’s markets include Arizona, California, Delaware, Florida, Maryland, New Jersey and New York. Together with affiliated radiologists, inclusive of full-time and per diem employees and technologists, RadNet has a total of over 9,700 employees. For more information, visit http://www.radnet.com.
Contact:
RadNet, Inc.
Mark Stolper, Executive Vice President and Chief Financial Officer
310-445-2928
Last Trade: | US$72.25 |
Daily Change: | -0.18 -0.25 |
Daily Volume: | 405,798 |
Market Cap: | US$5.350B |
January 08, 2025 December 04, 2024 December 02, 2024 December 02, 2024 December 01, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load